• Archer signs agreement with Hylid Diagnostics to develop at-home testing device for chronic kidney disease
• Archer and Hylid to combine their blood sensing technologies to accelerate development and create a prototype system
• Hylid specializes in medical devices for at-home blood testing and has advisors to aid regulatory processes and clinical trials

Archer Materials Limited (ASX: AXE), a semiconductor company advancing quantum technology and medical diagnostics, has signed an agreement with Canadian medical device company Hylid Diagnostics Inc to develop a potassium measurement product for testing chronic kidney disease in Archer's Biochip. The partnership will involve Archer's Biochip team utilizing its potassium sensing technology and Hylid's blood hemolysis sensor technology to develop a system that meets accuracy requirements for blood potassium measurements. Together, the teams will combine hemolysis and potassium sensing technologies and then integrate them into a prototype cartridge system. Hylid specializes in using novel optical sensors to bring affordable, lab-quality blood testing to the home, with their first target market being chronic kidney disease in North America and Europe. Hylid has a team of advisors in the US, Canada, and UK to aid in the entry of regulatory processes and the setup of clinical trials. The first stage of the joint project will be for Hylid to produce stand-alone hemolysis sensors that meet accuracy requirements, allowing for the integration of Archer's potassium sensing chips with the aim of developing an at-home testing device. Archer and Hylid will then design and begin manufacturing an integrated cartridge system suitable for early-stage clinical testing and volume production.

Archer and Hylid are now creating a detailed work plan for the next few months, including the first stage of the project which is to produce stand-alone hemolysis sensors that when used with Archer's Biochip will meet potassium measurement accuracy requirements.